{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T01:14:12Z","timestamp":1789434852789,"version":"build-2803163510"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T00:00:00Z","timestamp":1715558400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T00:00:00Z","timestamp":1715558400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001823","name":"Ministry of Education Youth and Sports","doi-asserted-by":"crossref","award":["ERDF No. CZ.02.1.01\/0.0\/0.0\/18_069\/0010054\u2014IT4Neuro(degeneration)"],"award-info":[{"award-number":["ERDF No. CZ.02.1.01\/0.0\/0.0\/18_069\/0010054\u2014IT4Neuro(degeneration)"]}],"id":[{"id":"10.13039\/501100001823","id-type":"DOI","asserted-by":"crossref"}]},{"name":"UHK FIM","award":["Excellence 2022"],"award-info":[{"award-number":["Excellence 2022"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>New effective treatments for dementia are lacking, and early prevention focusing on risk factors of dementia is important. Non-pharmacological intervention therapies aimed at these factors may provide a valuable tool for reducing the incidence of dementia. This study focused on the development of a mathematical model to predict the number of individuals with neurodegenerative diseases, specifically Alzheimer\u2019s disease, Parkinson\u2019s disease, vascular dementia, and amyotrophic lateral sclerosis. Scenarios for non-pharmacological intervention therapies based on risk factor reduction were also assessed. The estimated total costs and potential cost savings from societal were included.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Based on demographic and financial data from the EU, a mathematical model was developed to predict the prevalence and resulting care costs of neurodegenerative diseases in the population. Each disease (Alzheimer\u2019s disease, Parkinson\u2019s disease, vascular dementia, and amyotrophic lateral sclerosis) used parameters that included prevalence, incidence, and death risk ratio, and the simulation is related to the age of the cohort and the disease stage.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A replicable simulation for predicting the prevalence and resulting cost of care for neurodegenerative diseases in the population exhibited an increase in treatment costs from 267\u00a0billion EUR in 2021 to 528\u00a0billion EUR by 2050 in the EU alone. Scenarios related to the reduction of the prevalence of dementia by up to 20% per decade led to total discounted treatment cost savings of up to 558\u00a0billion EUR.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The model indicates the magnitude of the financial burden placed on EU healthcare systems due to the growth in the population prevalence of neurodegenerative diseases in the coming decades. Lifestyle interventions based on reducing the most common risk factors could serve as a prevention strategy to reduce the incidence of dementia with substantial cost-savings potential. These findings could support the implementation of public health approaches throughout life to ultimately prevent premature mortality and promote a healthier and more active lifestyle in older individuals.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12889-024-18773-7","type":"journal-article","created":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T08:01:54Z","timestamp":1715587314000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Nonpharmacological intervention therapies for dementia: potential break-even intervention price and savings for selected risk factors in the European healthcare system"],"prefix":"10.1186","volume":"24","author":[{"given":"Petra","family":"Maresova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Rezny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petr","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marian","family":"Valko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamil","family":"Kuca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,13]]},"reference":[{"issue":"18","key":"18773_CR1","first-page":"690","volume":"113","author":"M Boada","year":"1999","unstructured":"Boada M, Pe\u00f1a-Casanova J, Bermejo F, Guill\u00e9n F, Hart WM, Espinosa C, et al. [Costs of health care resources of ambulatory-care patients diagnosed with Alzheimer\u2019s disease in Spain]. Med Clin (Barc). 1999;113(18):690\u20135.","journal-title":"Med Clin (Barc)"},{"issue":"6","key":"18773_CR2","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1001\/archneur.1997.00550180013006","volume":"54","author":"RL Ernst","year":"1997","unstructured":"Ernst RL. Cognitive function and the costs of Alzheimer Disease: an exploratory study. Arch Neurol. 1997;54(6):687.","journal-title":"Arch Neurol"},{"issue":"1","key":"18773_CR3","doi-asserted-by":"publisher","first-page":"e0210958","DOI":"10.1371\/journal.pone.0210958","volume":"14","author":"R Cimler","year":"2019","unstructured":"Cimler R, Maresova P, Kuhnova J, Kuca K. Predictions of Alzheimer\u2019s disease treatment and care costs in European countries. PLoS ONE. 2019;14(1):e0210958.","journal-title":"PLoS ONE"},{"issue":"1","key":"18773_CR4","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jalz.2012.11.007","volume":"9","author":"M Prince","year":"2013","unstructured":"Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri CP. The global prevalence of dementia: a systematic review and metaanalysis. Alzheimers Dement. 2013;9(1):63.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"18773_CR5","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13195-014-0083-0","volume":"7","author":"M Ikeda","year":"2015","unstructured":"Ikeda M, Mori E, Matsuo K, Nakagawa M, Kosaka K. Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled, confirmatory phase III trial. Alzheimers Res Ther. 2015;7(1):4.","journal-title":"Alzheimers Res Ther"},{"issue":"3","key":"18773_CR6","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.jalz.2016.12.005","volume":"13","author":"A Gustavsson","year":"2017","unstructured":"Gustavsson A, Green C, Jones RW, F\u00f6rstl H, Simsek D, Reydet de Vulpillieres F, et al. Current issues and future research priorities for health economic modelling across the full continuum of Alzheimer\u2019s disease. Alzheimers Dement. 2017;13(3):312\u201321.","journal-title":"Alzheimers Dement"},{"issue":"9","key":"18773_CR7","doi-asserted-by":"publisher","first-page":"903","DOI":"10.2174\/156720501209151019111448","volume":"12","author":"P Maresova","year":"2015","unstructured":"Maresova P, Mohelska H, Dolejs J, Kuca K. Socio-economic aspects of Alzheimer\u2019s Disease. Curr Alzheimer Res. 2015;12(9):903\u201311.","journal-title":"Curr Alzheimer Res"},{"issue":"9","key":"18773_CR8","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/S1474-4422(11)70072-2","volume":"10","author":"DE Barnes","year":"2011","unstructured":"Barnes DE, Yaffe K. The projected effect of risk factor reduction on Alzheimer\u2019s disease prevalence. Lancet Neurol. 2011;10(9):819\u201328.","journal-title":"Lancet Neurol"},{"issue":"10","key":"18773_CR9","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/S1474-4422(12)70206-5","volume":"11","author":"B Vellas","year":"2012","unstructured":"Vellas B, Coley N, Ousset PJ, Berrut G, Dartigues JF, Dubois B, et al. Long-term use of standardised Ginkgo biloba extract for the prevention of Alzheimer\u2019s disease (GuidAge): a randomised placebo-controlled trial. Lancet Neurol. 2012;11(10):851\u20139.","journal-title":"Lancet Neurol"},{"issue":"8","key":"18773_CR10","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/S1474-4422(14)70136-X","volume":"13","author":"S Norton","year":"2014","unstructured":"Norton S, Matthews FE, Barnes DE, Yaffe K, Brayne C. Potential for primary prevention of Alzheimer\u2019s disease: an analysis of population-based data. Lancet Neurol. 2014;13(8):788\u201394.","journal-title":"Lancet Neurol"},{"key":"18773_CR11","unstructured":"O\u2019Neil ME, Freeman M, Christensen V, Telerant R, Addleman A, Kansagara D. A Systematic Evidence Review of Non-pharmacological Interventions for Behavioral Symptoms of Dementia [Internet]. Washington (DC): Department of Veterans Affairs; 2011 [cited 2022 Apr 2]. (VA Evidence-based Synthesis Program Reports). http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK54971\/."},{"issue":"1","key":"18773_CR12","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1097\/JGP.0b013e3181e043d0","volume":"19","author":"MS Beeri","year":"2011","unstructured":"Beeri MS, Goldbourt U. Late-Life Dementia predicts mortality beyond established midlife risk factors. Am J Geriatr Psychiatry. 2011;19(1):79\u201387.","journal-title":"Am J Geriatr Psychiatry"},{"issue":"1","key":"18773_CR13","doi-asserted-by":"publisher","first-page":"157","DOI":"10.3233\/JAD-2012-120808","volume":"33","author":"E L\u00f6nnroos","year":"2013","unstructured":"L\u00f6nnroos E, Kyyr\u00f6nen P, Bell JS, van der Cammen TJM, Hartikainen S. Risk of death among persons with Alzheimer\u2019s disease: a National Register-based nested case-control study. J Alzheimers Dis. 2013;33(1):157\u201364.","journal-title":"J Alzheimers Dis"},{"key":"18773_CR14","unstructured":"Georges J. Dementia in Europe Yearbook 2019 [Internet]. Alzheimer Europe; 2019. https:\/\/www.alzheimer-europe.org\/sites\/default\/files\/alzheimer_europe_dementia_in_europe_yearbook_2019.pdf."},{"key":"18773_CR15","unstructured":"World Alzheimer Report 2015, The Global Impact of Dementia: An analysis of prevalence, incidence, cost and trends.:87."},{"issue":"8","key":"18773_CR16","doi-asserted-by":"publisher","first-page":"777","DOI":"10.2174\/1567205015666180119092427","volume":"15","author":"M Davis","year":"2018","unstructured":"Davis M, O`Connell T, Johnson S, Cline S, Merikle E, Martenyi F, et al. Estimating Alzheimer\u2019s Disease Progression Rates from normal cognition through mild cognitive impairment and stages of Dementia. Curr Alzheimer Res. 2018;15(8):777\u201388.","journal-title":"Curr Alzheimer Res"},{"issue":"13","key":"18773_CR17","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1002\/mds.25898","volume":"29","author":"AD Macleod","year":"2014","unstructured":"Macleod AD, Taylor KSM, Counsell CE. Mortality in Parkinson\u2019s disease: a systematic review and meta-analysis. Mov Disord. 2014;29(13):1615\u201322.","journal-title":"Mov Disord"},{"issue":"13","key":"18773_CR18","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1002\/mds.25945","volume":"29","author":"T Pringsheim","year":"2014","unstructured":"Pringsheim T, Jette N, Frolkis A, Steeves TDL. The prevalence of Parkinson\u2019s disease: a systematic review and meta-analysis. Mov Disord off J Mov Disord Soc. 2014;29(13):1583\u201390.","journal-title":"Mov Disord off J Mov Disord Soc"},{"issue":"4","key":"18773_CR19","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1159\/000445751","volume":"46","author":"L Hirsch","year":"2016","unstructured":"Hirsch L, Jette N, Frolkis A, Steeves T, Pringsheim T. The incidence of Parkinson\u2019s Disease: a systematic review and Meta-analysis. Neuroepidemiology. 2016;46(4):292\u2013300.","journal-title":"Neuroepidemiology"},{"issue":"3\u20134","key":"18773_CR20","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1159\/000477165","volume":"78","author":"D Enders","year":"2017","unstructured":"Enders D, Balzer-Geldsetzer M, Riedel O, Dodel R, Wittchen HU, Sensken SC, et al. Prevalence, duration and severity of Parkinson\u2019s Disease in Germany: a combined Meta-analysis from Literature Data and Outpatient samples. Eur Neurol. 2017;78(3\u20134):128\u201336.","journal-title":"Eur Neurol"},{"issue":"2","key":"18773_CR21","doi-asserted-by":"publisher","first-page":"467","DOI":"10.3233\/JAD-131856","volume":"41","author":"S Garcia-Ptacek","year":"2014","unstructured":"Garcia-Ptacek S, Farahmand B, K\u00e5reholt I, Religa D, Cuadrado ML, Eriksdotter M. Mortality risk after Dementia diagnosis by dementia type and underlying factors: a cohort of 15,209 patients based on the Swedish Dementia Registry. J Alzheimers Dis. 2014;41(2):467\u201377.","journal-title":"J Alzheimers Dis"},{"issue":"11 Suppl 5","key":"18773_CR22","first-page":"S4","volume":"54","author":"A Lobo","year":"2000","unstructured":"Lobo A, Launer LJ, Fratiglioni L, Andersen K, Di Carlo A, Breteler MM, et al. Prevalence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts. Neurologic diseases in the Elderly Research Group. Neurology. 2000;54(11 Suppl 5):S4\u20139.","journal-title":"Neurology"},{"key":"18773_CR23","doi-asserted-by":"crossref","unstructured":"Rom\u00e1n GC. The Epidemiology of vascular dementia. In: Handbook of Clinical Neurology [Internet]. Elsevier; 2008 [cited 2022 May 17]. pp. 639\u201358. https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0072975207012596.","DOI":"10.1016\/S0072-9752(07)01259-6"},{"issue":"18","key":"18773_CR24","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1212\/WNL.0000000000002638","volume":"86","author":"ITS Coyle-Gilchrist","year":"2016","unstructured":"Coyle-Gilchrist ITS, Dick KM, Patterson K, V\u00e1zquez Rodr\u00edquez P, Wehmann E, Wilcox A, et al. Prevalence, characteristics, and survival of frontotemporal lobar degeneration syndromes. Neurology. 2016;86(18):1736\u201343.","journal-title":"Neurology"},{"issue":"1","key":"18773_CR25","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1159\/000487079","volume":"8","author":"F Mayer","year":"2018","unstructured":"Mayer F, Di Pucchio A, Lacorte E, Bacigalupo I, Marzolini F, Ferrante G, et al. An Estimate of attributable cases of Alzheimer Disease and Vascular Dementia due to modifiable risk factors: the impact of primary Prevention in Europe and in Italy. Dement Geriatr Cogn Disord Extra. 2018;8(1):60\u201371.","journal-title":"Dement Geriatr Cogn Disord Extra"},{"issue":"1","key":"18773_CR26","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13561-020-00285-w","volume":"10","author":"A Braun","year":"2020","unstructured":"Braun A, Kurzmann P, H\u00f6fler M, Haber G, Auer S. Cost of care for persons with dementia: using a discrete-time Markov chain approach with administrative and clinical data from the dementia service centres in Austria. Health Econ Rev. 2020;10(1):29.","journal-title":"Health Econ Rev"},{"key":"18773_CR27","doi-asserted-by":"crossref","unstructured":"Bruno G, Mancini M, Bruti G, Dell\u2019Agnello G, Reed C, COSTS AND RESOURCE USE ASSOCIATED WITH ALZHEIMER\u2019S DISEASE IN ITALY.: RESULTS FROM AN OBSERVATIONAL STUDY. J Prev Alzheimers Dis. 2017;1\u201310.","DOI":"10.14283\/jpad.2017.31"},{"issue":"8","key":"18773_CR28","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1007\/s10198-016-0842-x","volume":"18","author":"I Holmerov\u00e1","year":"2017","unstructured":"Holmerov\u00e1 I, Hort J, Rusina R, Wimo A, \u0160teffl M. Costs of dementia in the Czech Republic. Eur J Health Econ. 2017;18(8):979\u201386.","journal-title":"Eur J Health Econ"},{"issue":"1","key":"18773_CR29","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3233\/JAD-150600","volume":"50","author":"B Michalowsky","year":"2015","unstructured":"Michalowsky B, Thyrian JR, Eichler T, Hertel J, Wucherer D, Flessa S et al. TJ Lee editor 2015 Economic Analysis of Formal Care, Informal Care, and Productivity losses in primary care patients who screened positive for dementia in Germany. J Alzheimers Dis 50 1 47\u201359.","journal-title":"J Alzheimers Dis"},{"issue":"12","key":"18773_CR30","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1017\/S1041610217001211","volume":"29","author":"J Olazar\u00e1n","year":"2017","unstructured":"Olazar\u00e1n J, Ag\u00fcera-Ortiz L, Argim\u00f3n JM, Reed C, Ciudad A, Andrade P, et al. Costs and quality of life in community-dwelling patients with Alzheimer\u2019s disease in Spain: results from the GERAS II observational study. Int Psychogeriatr. 2017;29(12):2081\u201393.","journal-title":"Int Psychogeriatr"},{"issue":"3","key":"18773_CR31","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.jval.2012.02.003","volume":"15","author":"T Rapp","year":"2012","unstructured":"Rapp T, Andrieu S, Molinier L, Grand A, Cantet C, Mullins CD, et al. Exploring the relationship between Alzheimer\u2019s Disease Severity and Longitudinal costs. Value Health. 2012;15(3):412\u20139.","journal-title":"Value Health"},{"issue":"4","key":"18773_CR32","doi-asserted-by":"publisher","first-page":"723","DOI":"10.3233\/JAD-2011-110539","volume":"27","author":"JP Reese","year":"2011","unstructured":"Reese JP, He\u00dfmann P, Seeberg G, Henkel D, Hirzmann P, Rieke J, et al. Cost and care of patients with Alzheimer\u2019s Disease: clinical predictors in German Health Care settings. J Alzheimers Dis. 2011;27(4):723\u201336.","journal-title":"J Alzheimers Dis"},{"issue":"2","key":"18773_CR33","doi-asserted-by":"publisher","first-page":"385","DOI":"10.3233\/JAD-122392","volume":"36","author":"A Wimo","year":"2013","unstructured":"Wimo A, Reed CC, Dodel R, Belger M, Jones RW, Happich M, et al. The GERAS Study: a prospective observational study of costs and Resource Use in Community dwellers with Alzheimer\u2019s Disease in three European Countries \u2013 Study Design and Baseline findings. J Alzheimers Dis. 2013;36(2):385\u201399.","journal-title":"J Alzheimers Dis"},{"issue":"10","key":"18773_CR34","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1002\/mds.10507","volume":"18","author":"L Findley","year":"2003","unstructured":"Findley L, Aujla M, Bain PG, Baker M, Beech C, Bowman C, et al. Direct economic impact of Parkinson\u2019s disease: a research survey in the United Kingdom. Mov Disord. 2003;18(10):1139\u201345.","journal-title":"Mov Disord"},{"issue":"6","key":"18773_CR35","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1002\/mds.10262","volume":"17","author":"P Hagell","year":"2002","unstructured":"Hagell P, Nordling S, Reimer J, Grabowski M, Persson U. Resource use and costs in a Swedish cohort of patients with Parkinson\u2019s disease. Mov Disord off J Mov Disord Soc. 2002;17(6):1213\u201320.","journal-title":"Mov Disord off J Mov Disord Soc"},{"issue":"3","key":"18773_CR36","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/S1353-8020(02)00097-4","volume":"9","author":"T Ker\u00e4nen","year":"2003","unstructured":"Ker\u00e4nen T, Kaakkola S, Sotaniemi K, Laulumaa V, Haapaniemi T, Jolma T, et al. Economic burden and quality of life impairment increase with severity of PD. Parkinsonism Relat Disord. 2003;9(3):163\u20138.","journal-title":"Parkinsonism Relat Disord"},{"issue":"s1","key":"18773_CR37","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1111\/j.1468-1331.2005.01197.x","volume":"12","author":"P Lindgren","year":"2005","unstructured":"Lindgren P, von Campenhausen S, Spottke E, Siebert U, Dodel R. Cost of Parkinson\u2019s disease in Europe. Eur J Neurol. 2005;12(s1):68\u201373.","journal-title":"Eur J Neurol"},{"issue":"6","key":"18773_CR38","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1002\/mds.21360","volume":"22","author":"P McCrone","year":"2007","unstructured":"McCrone P, Allcock LM, Burn DJ. Predicting the cost of Parkinson\u2019s disease. Mov Disord. 2007;22(6):804\u201312.","journal-title":"Mov Disord"},{"issue":"2","key":"18773_CR39","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.euroneuro.2010.08.002","volume":"21","author":"S von Campenhausen","year":"2011","unstructured":"von Campenhausen S, Winter Y, Rodrigues e Silva A, Sampaio C, Ruzicka E, Barone P, et al. Costs of illness and care in Parkinson\u2019s Disease: an evaluation in six countries. Eur Neuropsychopharmacol. 2011;21(2):180\u201391.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"1","key":"18773_CR40","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.parkreldis.2009.07.005","volume":"16","author":"Y Winter","year":"2010","unstructured":"Winter Y, von Campenhausen S, Brozova H, Skoupa J, Reese JP, B\u00f6tzel K, et al. Costs of Parkinson\u2019s disease in Eastern Europe: a Czech cohort study. Parkinsonism Relat Disord. 2010;16(1):51\u20136.","journal-title":"Parkinsonism Relat Disord"},{"issue":"1\u20132","key":"18773_CR41","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3109\/21678421.2014.932384","volume":"16","author":"K Athanasakis","year":"2015","unstructured":"Athanasakis K, Kyriopoulos II, Sideris M, Rentzos M, Evdokimidis J, Kyriopoulos J. Investigating the economic burden of ALS in Greece: a cost-of-illness approach. Amyotroph Lateral Scler Front Degener. 2015;16(1\u20132):63\u20134.","journal-title":"Amyotroph Lateral Scler Front Degener"},{"issue":"10","key":"18773_CR42","doi-asserted-by":"publisher","first-page":"e0223772","DOI":"10.1371\/journal.pone.0223772","volume":"10","author":"J Darb\u00e0","year":"2019","unstructured":"Darb\u00e0 J. Current status and direct medical cost of amyotrophic lateral sclerosis in the region of Catalonia: a population-based analysis. PLoS ONE. 2019;10(10):e0223772.","journal-title":"PLoS ONE"},{"issue":"1","key":"18773_CR43","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00415-009-5256-6","volume":"257","author":"K Schepelmann","year":"2010","unstructured":"Schepelmann K, Winter Y, Spottke AE, Claus D, Grothe C, Schr\u00f6der R, et al. Socioeconomic burden of amyotrophic lateral sclerosis, myasthenia gravis and facioscapulohumeral muscular dystrophy. J Neurol. 2010;257(1):15\u201323.","journal-title":"J Neurol"},{"issue":"1","key":"18773_CR44","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/s13023-020-01413-9","volume":"15","author":"E Sch\u00f6nfelder","year":"2020","unstructured":"Sch\u00f6nfelder E, Osmanovic A, M\u00fcschen LH, Petri S, Schreiber-Katz O. Costs of illness in amyotrophic lateral sclerosis (ALS): a cross-sectional survey in Germany. Orphanet J Rare Dis. 2020;15(1):149.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"18773_CR45","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1080\/17482960802103131","volume":"10","author":"IVD Steen","year":"2009","unstructured":"Steen IVD, Berg JPVD, Buskens E, Lindeman E, Van Den Berg LH. The costs of amyotrophic lateral sclerosis, according to type of care. Amyotroph Lateral Scler. 2009;10(1):27\u201334.","journal-title":"Amyotroph Lateral Scler"},{"issue":"5","key":"18773_CR46","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3810\/pgm.2012.09.2597","volume":"124","author":"C Ramos\u2013Estebanez","year":"2012","unstructured":"Ramos\u2013Estebanez C, Moral\u2013Arce I, Rojo F, Gonzalez\u2013Macias J, Hernandez JL. Vascular cognitive impairment and dementia expenditures: 7\u2013Year inpatient cost description in Community dwellers. Postgrad Med. 2012;124(5):91\u2013100.","journal-title":"Postgrad Med"},{"key":"18773_CR47","unstructured":"Eurostat. Statistics | Eurostat [Internet]. [cited 2023 Apr 29]. https:\/\/ec.europa.eu\/eurostat\/databrowser\/view\/SDG_08_10__custom_5679006\/default\/table?lang=en."},{"issue":"3","key":"18773_CR48","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.jalz.2007.04.381","volume":"3","author":"R Brookmeyer","year":"2007","unstructured":"Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. Forecasting the global burden of Alzheimer\u2019s disease. Alzheimers Dement. 2007;3(3):186\u201391.","journal-title":"Alzheimers Dement"},{"key":"18773_CR49","unstructured":"Aldus CF, Arthur A, Dennington-Price A, Millac P, Richmond P, Dening T et al. Discussion [Internet]. Undiagnosed dementia in primary care: a record linkage study. NIHR Journals Library; 2020 [cited 2022 May 17]. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK555879\/."},{"issue":"7","key":"18773_CR50","first-page":"P1635","volume":"15","author":"P Pedroza","year":"2019","unstructured":"Pedroza P, Chakrabarti S, Chapin A, Liu A, Matyasz T, Dieleman JL. COSTS OF ALZHEIMER\u2019S DISEASE AND DEMENTIA IN 188 COUNTRIES. Alzheimers Dement. 2019;15(7):P1635.","journal-title":"Alzheimers Dement"},{"key":"18773_CR51","unstructured":"Eurostat. Eurodindicators [Internet]. Eurostat. 2022. https:\/\/ec.europa.eu\/eurostat\/documents\/2995521\/14442438\/2-01042022-AP-EN.pdf\/ba153bc6-c1aa-f6e5-785b-21c83f5319e5."},{"issue":"4","key":"18773_CR52","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1590\/1980-57642016dn11-040005","volume":"11","author":"N Custodio","year":"2017","unstructured":"Custodio N, Montesinos R, Lira D, Herrera-P\u00e9rez E, Bardales Y, Valeriano-Lorenzo L. Mixed dementia: a review of the evidence. Dement Neuropsychol. 2017;11(4):364\u201370.","journal-title":"Dement Neuropsychol"},{"key":"18773_CR53","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1016\/S0140-6736(15)60461-5","volume":"385","author":"T Ngandu","year":"2015","unstructured":"Ngandu T, Lehtisalo J, Solomon A, Lev\u00e4lahti E, Ahtiluoto S, Antikainen R, B\u00e4ckman L, H\u00e4nninen T, Jula A, Laatikainen T, Lindstr\u00f6m J, Mangialasche F, Paajanen T, Pajala S, Peltonen M, Rauramaa R, Stigsdotter-Neely A, Strandberg T, Tuomilehto J, Soininen H, Kivipelto M. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet. 2015;385:2255\u201363.","journal-title":"Lancet"},{"key":"18773_CR54","unstructured":"Finnisch Institute for health and welfare. FINGER research project results. https:\/\/thl.fi\/en\/research-and-development\/research-and-projects\/finger-research-project\/results."},{"issue":"10046","key":"18773_CR55","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S0140-6736(16)30950-3","volume":"388","author":"EP van Moll","year":"2016","unstructured":"van Moll EP, Richard E, Eurelings LS, et al. Effectiveness of a 6-year multidomain vascular care intervention to prevent dementia (preDIVA): a cluster-randomised controlled trial. Lancet. 2016;388(10046):797\u2013805.","journal-title":"Lancet"},{"issue":"1","key":"18773_CR56","first-page":"13","volume":"1","author":"B Vellas","year":"2014","unstructured":"Vellas B, Carrie I, Gillette-Guyonnet S, et al. MAPT study: a multidomain approach for preventing Alzheimer\u2019s disease: design and baseline data. J Prev Alzheimers Dis. 2014;1(1):13\u201322.","journal-title":"J Prev Alzheimers Dis"},{"key":"18773_CR57","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1186\/s13195-023-01325-3","volume":"15","author":"J Delrieu","year":"2023","unstructured":"Delrieu J, Vellas B, Guyonnet S, et al. Cognitive impact of multidomain intervention and omega 3 according to blood A\u03b242\/40 ratio: a subgroup analysis from the randomized MAPT trial. Alz Res Therapy. 2023;15:183. https:\/\/doi.org\/10.1186\/s13195-023-01325-3.","journal-title":"Alz Res Therapy"},{"key":"18773_CR58","unstructured":"Food and Agriculture Organization. Cost and affordability of a healthy diet: an update. 2022. https:\/\/www.fao.org\/3\/cc0639en\/online\/sofi-2022\/cost-affordability-healthy-diet.html."},{"key":"18773_CR59","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1478-7547-8-9","volume":"8","author":"LA Hagberg","year":"2010","unstructured":"Hagberg LA, Lindholm L. Measuring the time costs of exercise: a proposed measuring method and a pilot study. Cost Eff Resour Alloc. 2010;8:9.","journal-title":"Cost Eff Resour Alloc"}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-024-18773-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12889-024-18773-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-024-18773-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T09:06:15Z","timestamp":1715591175000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpublichealth.biomedcentral.com\/articles\/10.1186\/s12889-024-18773-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,13]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["18773"],"URL":"https:\/\/doi.org\/10.1186\/s12889-024-18773-7","relation":{},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,13]]},"assertion":[{"value":"2 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1293"}}